A Phase 2 randomized controlled trial of metformin in high-risk idiopathic pulmonary fibrosis
Not Yet Recruiting Phase 3 NCT07520110
Study Description
A study testing whether metformin can slow lung function decline in people with idiopathic pulmonary fibrosis who are at high risk for worsening disease
Study Details
- Registry ID:
- NCT07520110
- Conditions:
- Idiopathic Pulmonary Fibrosis
- Phase:
- Phase 3
- Target Enrollment:
- 800 participants
- Start Date:
- Age Range:
- 40–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
University of Massachusetts Chan Medical School
Worcester, Massachusetts, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.